Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19958957 | 0.95 | ODC1 (0.36) | ODC1CYP3A4GBA2 | |
| SCHEMBL12826391 | 0.95 | ODC1 (0.39) | ODC1CYP3A4GBA2 | |
| SCHEMBL19958956 | 0.93 | GBA2 (0.35) | GBA2 | |
| SCHEMBL22692188 | 0.88 | GBA2 (0.32) | GBA2 | |
| SCHEMBL26122502 | 0.88 | GBA2 (0.37) | ODC1GBA2 | |
| SCHEMBL19958958 | 0.86 | GBA2 (0.37) | GBA2 | |
| SCHEMBL20314465 | 0.86 | GBA2 (0.33) | GBA2 | |
| SCHEMBL26122170 | 0.86 | GBA2 (0.39) | GBA2 | |
| SCHEMBL26124266 | 0.86 | GBA2 (0.39) | GBA2 | |
| SCHEMBL20128688 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ODC1 2923/4885CYP3A4 4716/4885GBA2 2592/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ODC1 2896/4885CYP3A4 4541/4885GBA2 3290/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ODC1 2998/4885CYP3A4 4464/4885GBA2 4133/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ODC1 3454/4885CYP3A4 258/4885GBA2 4212/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | ODC1 3371/4885CYP3A4 4731/4885GBA2 2552/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | ODC1 3396/4885CYP3A4 4712/4885GBA2 3416/4885 |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ODC1 2896/4885CYP3A4 4541/4885GBA2 3290/4885 |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | ODC1 3414/4885CYP3A4 4860/4885GBA2 2442/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | ODC1 3460/4885CYP3A4 4173/4885GBA2 2658/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ODC1 1899/4885CYP3A4 4840/4885GBA2 2176/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | ODC1 1899/4885CYP3A4 4840/4885GBA2 2176/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ODC1 2896/4885CYP3A4 4541/4885GBA2 3290/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ODC1 2923/4885CYP3A4 4716/4885GBA2 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.